Age Related Macular Degeneration Clinical Trials 2023

What are the top hospitals conducting age related macular degeneration research?

When it comes to revolutionary clinical trials aimed at combating age-related macular degeneration (AMD), several hospitals are leading the charge. In Reno, Sierra Eye Associates takes the spotlight with an impressive portfolio of 10 ongoing AMD trials and a total of 48 completed studies dedicated to this condition. Since conducting their first trial in 2013, Sierra Eye Associates has been at the forefront of exploring innovative treatments for AMD. Meanwhile, Cumberland Valley Retina Consultants in Hagerstown is making significant strides as well, currently undertaking nine active clinical trials focused on AMD and having completed 16 previous investigations since their inaugural study in 2012.

Texas also proves its commitment to advancing knowledge about AMD through two prominent institutions: Retina Consultants of Texas in Bellaire and The Woodlands. Both locations actively engage in research efforts with nine and eight ongoing clinical trials respectively for AMD. With a combined history encompassing 41 studies between them dating back to their earliest recorded trial in 2015 (Bellaire) and more recently starting from only three years ago (The Woodlands), these institutions demonstrate dedication towards finding new approaches to managing this debilitating eye disease.

Back on the East Coast, Ophthalmic Consultants of Boston plays a vital role by conducting seven active clinical trials targeting age-related macular degeneration while contributing valuable insights from their extensive experience spanning over four decades - they have conducted an impressive total of43 such studies since embarking upon their first investigation into this condition way back in1999.

These hospitals' commitment showcases not only advancements made thus far but also fosters hope for millions impacted by age-related macular degeneration worldwide. As science continues evolving alongside medical expertise within these top-tier facilities, each breakthrough serves as a stepping stone toward improved management and potential cures for this sight-threatening ailment

Which are the best cities for age related macular degeneration clinical trials?

When it comes to age-related macular degeneration clinical trials, several cities show promising advancements in research and treatment options. Phoenix, Arizona leads the way with 32 active trials, investigating therapies like RGX-314, IONIS-FB-LRx, and ADVM-022. Austin, Texas closely follows with 29 ongoing studies focused on IONIS-FB-LRx, RGX-314, and Faricimab. Boston, Massachusetts and Philadelphia, Pennsylvania both have 25 active trials each that explore treatments such as RGX-314 Dose 2 and PEGCETACOPLAN (APL-2). Lastly Baltimore,Maryland offers a location where 24 active trials are investigating potential breakthroughs including RGX-314 and JNJ-81201887 High dose. These cities provide individuals with age-related macular degeneration access to cutting-edge clinical trials that hold valuable promise for improved vision outcomes.

Which are the top treatments for age related macular degeneration being explored in clinical trials?

Clinical trials are paving the way for advancements in the treatment of age-related macular degeneration (AMD). The top contenders include ALK-001, currently undergoing two active trials and contributing to a total of two AMD clinical trials since its introduction in 2015. Another promising candidate is RGX-314, which has shown potential with two ongoing trials and four all-time AMD studies since its listing in 2017. Also making waves is RGX-314 Dose 2, newly listed in 2020 but already making an impact with two ongoing AMD trials. These treatments signify hope for individuals affected by this debilitating eye condition as researchers bring us closer to effective solutions through their tireless efforts in clinical research.

What are the most recent clinical trials for age related macular degeneration?

Promising clinical trials have emerged in the field of age-related macular degeneration, offering hope for patients grappling with this condition. One notable trial is NG101 Gene Therapy Group 1, which has entered Phase 2 after showing encouraging results in Phase 1. Another study investigates an experimental treatment involving low-dose escalation aimed at addressing the progression of macular degeneration. Additionally, KH631 Dose 1 and CT1812 200 mg have demonstrated potential benefits for individuals affected by age-related macular degeneration. As these innovative trials continue to progress through different phases, they hold promise for improving outcomes and quality of life for those battling this vision-threatening disease.

What age related macular degeneration clinical trials were recently completed?

Several recent clinical trials have made significant progress in the field of age-related macular degeneration (AMD). In May 2022, Sandoz successfully completed a trial investigating SOK583A1. Additionally, Kodiak Sciences Inc. concluded their research on KSI-301 in June 2021, while Maturi, Raj K., M.D., P.C. wrapped up their study on RBM-007 Injectable Solution during the same month. These trials represent important milestones in our ongoing efforts to understand and find effective treatments for AMD, offering hope to individuals affected by this condition.